IcoSema (insulin icodec + semaglutide) pharmacokinetics to be characterized in Chinese Type 2 Diabetes

Managing Type 2 Diabetes often requires complex regimens, including insulin and GLP-1 receptor agonists, to achieve optimal glycemic control. Current daily insulin injections and separate GLP-1 agonist doses can lead to adherence challenges. A novel fixed-ratio combination, IcoSema, combines insulin icodec (a new weekly basal insulin) and semaglutide (a weekly GLP-1 receptor analogue) into a single weekly injection. This aims to simplify treatment, potentially improving patient compliance and overall outcomes by targeting multiple pathways of glucose regulation.

This study employed a randomized, open-label, 3-period crossover design to assess the pharmacokinetic (PK) profiles of IcoSema (a fixed-ratio combination of insulin icodec and semaglutide), insulin icodec alone, and semaglutide alone. Participants were Chinese individuals with Type 2 Diabetes. Each participant received all three treatments via subcutaneous injection in the thigh at three different timepoints, with a 6 to 9-week washout period between injections. The order of administration was randomized. The study involved 31 or 32 clinic visits over 19 to 26 weeks, including three in-house stays of 5 or 6 days to facilitate intensive blood sampling for PK analysis.

This study is a completed protocol, and specific results detailing the pharmacokinetic profiles are not yet published in the provided abstract. The primary objective was to characterize how insulin icodec and semaglutide reach and remain in the blood of Chinese individuals with Type 2 Diabetes when administered as the novel fixed-ratio combination IcoSema, compared to when each component is given alone. Researchers aimed to understand the absorption, distribution, and elimination characteristics of these compounds. This foundational PK analysis is crucial for informing future clinical development, optimizing dosing strategies, and ensuring the safety and efficacy of this promising once-weekly combination therapy. The study's completion indicates that the data has been collected and is awaiting analysis and publication.